The healthcare sector has certainly not been the defensive sector many had hoped for during 2004. Pa...
The healthcare sector has certainly not been the defensive sector many had hoped for during 2004. Patent expiries, drug specific disappointments and changes to Medicare/Medicaid all caused sentiment towards the sector to turn south. Although pharmaceuticals and some of the larger biotech companies will indeed suffer from price cuts on drugs in the US, it is expected that the increase in volumes will offset this for a large part. Patent expiries will continue to affect the large pharma companies but other companies will benefit. The sector is supported by demographic trends in the US, Europe...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes